Investors like what they heard from GW Pharma at epilepsy meeting

|About: GW Pharmaceuticals plc (GWPH)|By:, SA News Editor

Shares of GW Pharmaceuticals (GWPH +11.9%) pop on a 2x surge in volume in early trading. Investors seem to like what they heard during the company's Epidiolex presentation at the Dravet Syndrome conference this past weekend. Several weeks ago, the company reported preliminary results from a clinical trial demonstrating a significant reduction in seizures in the the Epidiolex-treated cohort.

Epiolex is designated an Orphan Drug for Dravet and Lennox-Gastaut syndromes.

Recently, the FDA designated another cannabadiol product from Insys Therapeutics (INSY +1.6%) an Orphan Drug for the treatment of Lennox-Gastaut syndrome.